Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sammy Chebon

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|April 30, 2019
Marginalized models for right-truncated and interval-censored time-to-event dataSammy Chebon, Christel Faes, Ann De Smedt, et al.
Statistics in Medicine|October 14, 2016
Models for zero-inflated, correlated count data with extra heterogeneity: when is it too complex?Sammy Chebon, Christel Faes, Frank Cools, et al.
Pharmaceutical Statistics|May 9, 2015
Flexible modelling of simultaneously interval censored and truncated time-to-event dataSammy Chebon, Christel Faes, Ann De Smedt, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 12, 2021
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional studyJohannes Oldenburg, Huyen Tran, Flora Peyvandi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 4, 2021
Low immunogenicity of emicizumab in persons with haemophilia AChristophe Schmitt, Thomas Emrich, Sammy Chebon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2019
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world settingRebecca Kruse-Jarres, Johannes Oldenburg, Elena Santagostino, et al.
Current Medical Research and Opinion|July 30, 2019
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trialAdriana Reyes, Cédric Révil, Markus Niggli, et al.
Current Medical Research and Opinion|March 18, 2020
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087Adriana Reyes, Cédric Révil, Markus Niggli, et al.
Pediatric Blood & Cancer|August 11, 2020
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional studyJohannes Oldenburg, Midori Shima, Rebecca Kruse-Jarres, et al.
Research and Practice in Thrombosis and Haemostasis|September 29, 2022
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3Michael U Callaghan, Elina Asikanius, Michaela Lehle, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|April 30, 2019
Marginalized models for right-truncated and interval-censored time-to-event dataSammy Chebon, Christel Faes, Ann De Smedt, et al.
Statistics in Medicine|October 14, 2016
Models for zero-inflated, correlated count data with extra heterogeneity: when is it too complex?Sammy Chebon, Christel Faes, Frank Cools, et al.
Pharmaceutical Statistics|May 9, 2015
Flexible modelling of simultaneously interval censored and truncated time-to-event dataSammy Chebon, Christel Faes, Ann De Smedt, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 12, 2021
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional studyJohannes Oldenburg, Huyen Tran, Flora Peyvandi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 4, 2021
Low immunogenicity of emicizumab in persons with haemophilia AChristophe Schmitt, Thomas Emrich, Sammy Chebon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2019
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world settingRebecca Kruse-Jarres, Johannes Oldenburg, Elena Santagostino, et al.
Current Medical Research and Opinion|July 30, 2019
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trialAdriana Reyes, Cédric Révil, Markus Niggli, et al.
Current Medical Research and Opinion|March 18, 2020
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087Adriana Reyes, Cédric Révil, Markus Niggli, et al.
Pediatric Blood & Cancer|August 11, 2020
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional studyJohannes Oldenburg, Midori Shima, Rebecca Kruse-Jarres, et al.
Research and Practice in Thrombosis and Haemostasis|September 29, 2022
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3Michael U Callaghan, Elina Asikanius, Michaela Lehle, et al.
Pageof 2